In addition, the Ephrin-B2-Fc/EPHB4 interaction reduced the in vitro proliferation of rhabdomyosarcoma cells, prolonged the in vivo survival of rhabdomyosarcoma xenografts mice, and suppressed the growth rates of their primary tumors after receiving EPHB4-CAR-T cells compared to CD19-CAR-T cells (control) therapy [38]. Here, CD19 is linked to rhabdomyosarcoma.